

GZBM Triumph3 Retatrutide A Clinical phase III trial to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)

Study location [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Principal Investigators Drs. Tom Elliott and David Lee

Study coordinator & primary contact Dr. Marla Inducil P: 604-628-7253 x 7011 :

minducil@bcdiabetes.ca

Summary:

TRIUMPH 3 is a phase III RCT testing the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (drug:placebo ratio of 1:1:2)

Hypothesis: LY3437943 (retatrutide) shows potent agonist activity at GIP, GLP-1, and glucagon receptors. The mechanism of LY3437943 has the potential to deliver substantial body weight reduction across the spectrum of obesity, including individuals with severe obesity.

Eligible Participants include:

- Male or female >18 yrs of age
- Established CVD
- BMI ≥ 35 kg/m²
- Non-Type 2 (A1c < 6.5%)
OR
- T2DM with A1c between 6.5-10.5%, disallowed medications include: DPP4, GLP1, rapid insulin, insulin pump, or U500 insulin
- Documentation of at least 1 self-reported unsuccessful dietary effort to reduce body weight
- eGFR >30
- FPG < 15 mmol/L

Treatment course and duration: 113 weeks, monthly visits

Odds of receiving placebo:(50%)

Study documents:

[Protocol](#) [Consent form](#) [Ethics Approval](#) [Ethics renewal](#) [Conflict of Interest statement](#)

Short URL to this document: <https://bit.ly/BCD-GZBM>